Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG2737 Single Dose PK in Male CF Patients
NCT03450720Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jun 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GLPG2737 in cystic fibrosis (CF), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration at 48 hours, Time of occurrence of Cmax at 48 hours and 5 more. Started Jun 2017; status: completed.
02
Drugs
GLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03450720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450720.